Pharmacogenetic Factors in Antimalarial Drug Testing
The pharmacogenetic factors that are of importance in antimalarial drug testing (which in the final analysis must be conducted in the endemic areas) are (a) red-cell genetic factors, (b) acetylator phenotype and, possibly, (c) blood groups.
KeywordsSickle Cell Disease Sickle Cell G6PD Deficiency Sickle Cell Trait Acetylator Phenotype
Unable to display preview. Download preview PDF.
- Choudhry VP, Nishi M, Sood SK, Ghai OP (1977) Chloroquine induced haemolysis and acute renal failure in subjects with G-6-PD deficiency. Trop Geogr Med 30:331–335Google Scholar
- Kojo Addae S (1975) The kidney in sickle cell disease. Ghana Universities Press, AccraGoogle Scholar
- Sietsma A, Naughton MA, Harley JD (1968) “Blue soldiers.” Med J Aust 55:911Google Scholar
- Sietsma A, Naughton MA, Harley JD (1971) Methaemoglobin levels in soldiers receiving antimalarial drugs. Med J Aust 58:473–475Google Scholar
- Sunahara S (1961) Genetic geographical and clinical studies on isoniazid metabolism. In: Proceedings of the XVI international tuberculosis conference, Toronto, Canada. Ex-cerpta Medica, Amsterdam (Excerpta Medica International Congress Series No. 44, pp 513–540)Google Scholar
- Weatherall DJ, Clegg JB (1972) The thalassaemia syndromes, 2edn. Blackwell, OxfordGoogle Scholar